ReShape Operating Margin from 2010 to 2024
| RSLS Stock | USD 0.17 0 0.65% |
Check ReShape Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ReShape main balance sheet or income statement drivers, such as Other Operating Expenses of 26.5 M, Total Operating Expenses of 24.6 M or Income Tax Expense of 49.4 K, as well as many exotic indicators such as Price To Sales Ratio of 0.16, Dividend Yield of 0.0 or PTB Ratio of 0.21. ReShape financial statements analysis is a perfect complement when working with ReShape Lifesciences Valuation or Volatility modules.
ReShape | Operating Margin |
Latest ReShape Lifesciences' Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of ReShape Lifesciences over the last few years. It is ReShape Lifesciences' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ReShape Lifesciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (0.96) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
ReShape Operating Margin Regression Statistics
| Arithmetic Mean | (42.01) | |
| Coefficient Of Variation | (94.40) | |
| Mean Deviation | 36.35 | |
| Median | (28.98) | |
| Standard Deviation | 39.65 | |
| Sample Variance | 1,573 | |
| Range | 94.382 | |
| R-Value | 0.84 | |
| Mean Square Error | 508.18 | |
| R-Squared | 0.70 | |
| Significance | 0.0001 | |
| Slope | 7.42 | |
| Total Sum of Squares | 22,015 |
ReShape Operating Margin History
About ReShape Lifesciences Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include ReShape Lifesciences income statement, its balance sheet, and the statement of cash flows. ReShape Lifesciences investors use historical funamental indicators, such as ReShape Lifesciences's Operating Margin, to determine how well the company is positioned to perform in the future. Although ReShape Lifesciences investors may use each financial statement separately, they are all related. The changes in ReShape Lifesciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ReShape Lifesciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on ReShape Lifesciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in ReShape Lifesciences. Please read more on our technical analysis and fundamental analysis pages.
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California. Reshape Lifesciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 47 people.
Currently Active Assets on Macroaxis
When determining whether ReShape Lifesciences is a strong investment it is important to analyze ReShape Lifesciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ReShape Lifesciences' future performance. For an informed investment choice regarding ReShape Stock, refer to the following important reports:Check out the analysis of ReShape Lifesciences Correlation against competitors. For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for ReShape Stock analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is ReShape Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ReShape Lifesciences. If investors know ReShape will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ReShape Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Revenue Per Share 1.457 | Quarterly Revenue Growth (0.36) | Return On Assets (0.84) | Return On Equity (2.21) |
The market value of ReShape Lifesciences is measured differently than its book value, which is the value of ReShape that is recorded on the company's balance sheet. Investors also form their own opinion of ReShape Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is ReShape Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ReShape Lifesciences' market value can be influenced by many factors that don't directly affect ReShape Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ReShape Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ReShape Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ReShape Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.